World Skin Cancer Therapeutics Market: Growth, Trends, Company Profiles, and Forecasts (2019-2024) – ResearchAndMarkets.com
April 30, 2019DUBLIN–(BUSINESS WIRE)–The “Skin
Cancer Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The global skin cancer therapeutics market is expected to witness a CAGR
of 10.4% during the forecast period. Certain factors driving the market
growth include increased incidence of skin cancer, extensive R&D
pipelines, and raising awareness about skin cancer.
Even though most types of skin cancers are preventable, its incidence is
increasing. People can recognize changes in their skin during the early
stages of the disease. The risk factors include sunlight, sunlamps and
tanning booths, certain medical conditions, or medicines. The UV
radiation changes the genetic material (DNA) in cells and is, therefore,
the main cause of skin cancer.
According to the American Cancer Society, exposure to the sun is the
most preventable risk factor for all skin cancers. According to the
National Cancer Institute, the rate of new melanoma cases among American
adults has tripled since the 1970s, from 7.9 per 100,000 people in 1975
to 25.2 per 100,000 in 2014. The rate of new melanoma cases among both
men and women has been increasing at 1.7% and 1.4% per year
respectively, as per the data of Federal Centers for Disease Control and
Prevention (CDC). Thus, the increasing prevalence of skin cancer is
augmenting the growth of the market studied.
However, a common side effect of radiation therapy is skin irritation in
the area of the body that is being treated. The skin reaction can range
from mild redness and dryness (similar to a sunburn) to severe peeling
(desquamation) of the skin in some patients. The majority of skin
reactions to radiation therapy go away a few weeks after the treatment
is completed.
In some cases, the treated skin will remain slightly darker than it was
before and may continue to be more sensitive to sun exposure. About two
to three weeks after first radiation treatment, redness is noticed and
irritation is similar to a sunburn. The skin may be itchy, dry, red, or
sore. There are also long-term side effects, like changes in skin color,
lung problems, and others, which act as major restraints for the growth
of the market studied.
Key Market Trends
Non-melanoma is Expected to Hold a Significant Market Share in the
Disease Type
According to the ASCO (American Society of Clinical Oncology), it is
estimated that more than 3 million people in the United States are
diagnosed with non-melanoma skin cancer each year. Basal cell carcinoma
is far more common than squamous cell carcinoma.
About 80% of non-melanoma skin cancer is basal cell carcinoma.
Similarly, the CCS (Canadian Cancer Society) states that non-melanoma
skin cancer is the most common cancer diagnosed among Canadians. It
makes up at least 40% of all new cancer cases in Canada.
North America Dominates the Market and is Expected to do Same in the
Forecast Period
North America is expected to dominate the market in the forecast period.
As per the American Academy of Dermatology, skin cancer is the most
common cancer in the United States. Most cases of melanoma, the
deadliest kind of skin cancer, are caused by exposure to ultraviolet
(UV) light.
It is estimated that approximately 9,500 people in the United States are
diagnosed with skin cancer every day. Thus, the increasing incidences of
skin cancer in the region is a major factor driving the growth of the
market studied. Additionally, the recent advancements of skin cancer
therapy, including photodynamic therapy (PDT), have been widely used in
treating non-melanoma skin malignancies, thus boosting the growth of the
market studied during the forecast period.
Competitive Landscape
The global skin cancer therapeutics market is highly competitive and
consists of a number of major players. Companies, like Amgen, Inc.,
Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, F.
Hoffmann-La Roche Ltd, Merck & Co., Inc., Mylan N.V., Novartis AG, Sun
Pharmaceutical Industries Ltd., and Varian Medical Systems, Inc., among
others, hold the substantial market share in the skin cancer
therapeutics market.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Skin Cancer
4.2.2 Extensive R&D Pipelines
4.2.3 Rising Awareness about Skin Cancer
4.3 Market Restraints
4.3.1 Side Effects and Complications Associated with Treatment
4.3.2 Stringent Regulatory Guidelines
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 Disease Type
5.1.1 Melanoma
5.1.2 Non-melanoma
5.2 Treatment
5.2.1 Chemotherapy
5.2.2 Radiotherapy
5.2.3 Cryosurgery
5.2.4 Immunotherapy
5.2.5 Photodynamic Therapy
5.2.6 Surgery
5.2.7 Other Treatments
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Daiichi Sankyo Company Limited
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Merck & Co. Inc.
6.1.6 Mylan N.V.
6.1.7 Novartis AG
6.1.8 Sun Pharmaceutical Industries Ltd.
6.1.9 Varian Medical Systems Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/oc4d5b
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Skin
Cancer Drugs, Dermatological
Drugs